Overview of current immunotherapeutic strategies for glioma

Immunotherapy

Volumn 7, Issue 10, 2015, Pages 1073-1104

  Calinescu, Anda Alexandra ^a   Kamran, Neha ^a   Baker, Gregory ^a   Mineharu, Yohei ^b   Lowenstein, Pedro Ricardo ^a   Castro, Maria Graciela ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

clinical trials; dendritic cells; gene therapy; glioma; immune checkpoints blockade; immunotherapy; vaccination

Indexed keywords

ARGININE; BASILIXIMAB; BEVACIZUMAB; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DURVALUMAB; GALUNISERTIB; GAMMA INTERFERON; GANCICLOVIR; ICT 121; IMIQUIMOD; IMMUNE STIMULATORY ADJUVANT; IMMUNOLOGICAL ADJUVANT; NIVOLUMAB; ONCOLYTIC VIRUS; ONCOLYTIC VIRUS AD5DELTA24; ONCOLYTIC VIRUS ONYX 015; PEMBROLIZUMAB; PEPTIDE VACCINE; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RINDOPEPIMUT; SYNTHETIC PEPTIDE VACCINE; TEMOZOLOMIDE; TUMOR CELL VACCINE; TUMOR LYSATE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALLOGENEIC T CELL TRANSFER; AUTOLOGOUS NATURAL KILLER CELL TRANSFER; AUTOLOGOUS NATURAL KILLER T CELL TRANSFER; AUTOLOGOUS T CELL TRANSFER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE CHECKPOINT; IMMUNE STIMULATORY GENE THERAPY; IMMUNOMODULATION; IMMUNOTHERAPY; LASER SURGERY; MONOTHERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PASSIVE IMMUNOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; HEALTH CARE QUALITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PERSONALIZED MEDICINE; PROCEDURES; TREATMENT FAILURE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; PRECISION MEDICINE; STANDARD OF CARE; TREATMENT FAILURE;

EID: 84971613070     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.75     Document Type: Review

References (207)

1. Doll R, Kinlen L. Immunosurveillance and cancer: epidemiological evidence. Br. Med. J. 4(5732), 420-422 (1970).
2. Greene HS. Heterotransplantation of tumors. Ann. NY Acad. Sci. 69(4), 818-829 (1957).
3. Baldwin RW, Robins RA. Factors interfering with immunological rejection of tumours. Br. Med. Bull. 32(2), 118-123 (1976).
4. Burnet FM. Immunological aspects of malignant disease. Lancet 1(7501), 1171-1174 (1967).
5. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
6. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72(9), 2162-2171 (2012).
7. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006).
8. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25(2), 214-221 (2013).
9. Mehling M, Simon P, Mittelbronn M et al. WHO grade associated downregulation of MHC class I antigenprocessing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 114(2), 111-119 (2007).
10. Anderson RC, Anderson DE, Elder JB et al. Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 60(6), 1129-1136; discussion 1136 (2007).
11. Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63(21), 7462-7467 (2003).
12. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
13. Didenko VV, Ngo HN, Minchew C, Baskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg. 96(3), 580-584 (2002).
14. Raychaudhuri B, Rayman P, Ireland J et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 13(6), 591-599 (2011).
15. Sippel TR, White J, Nag K et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin. Cancer Res. 17(22), 6992-7002 (2011).
16. Larsen SK, Gao Y, Basse PH. NK cells in the tumor microenvironment. Crit. Rev. Oncog. 19(1-2), 91-105 (2014).
17. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J. Biomed. Biotechnol. 2011, 676198 (2011).
18. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44(6), 1582-1592 (2014).
19. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 27(45), 5932-5943 (2008).
20. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol. 12(1), 7-13 (2010).
21. Baker GJ, Chockley P, Yadav VN et al. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 74(18), 5079-5090 (2014).
22. Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front. Immunol. 5, 543 (2014).
23. Ostrom QT, Gittleman H, Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 15(Suppl. 2), ii1-ii56 (2013).
24. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin. Oncol. 25(26), 4127-4136 (2007).
25. Ostrom QT, Bauchet L, Davis FG et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 16(7), 896-913 (2014).
26. Burrell RA, Mcgranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467), 338-345 (2013).
27. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108(3), 479-485 (2013).
28. Patel AP, Tirosh I, Trombetta JJ et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344(6190), 1396-1401 (2014).
29. Sottoriva A, Spiteri I, Piccirillo SG et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110(10), 4009-4014 (2013).
30. Kane JR, Miska J, Young JS, Kanojia D, Kim JW, Lesniak MS. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol. 17(Suppl. 2), ii24-ii36 (2015).
31. Chen KS, Mitchell DA. Monoclonal antibody therapy for malignant glioma. Adv. Exp. Med. Biol. 746, 121-141 (2012).
32. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
33. Morgan RA, Johnson LA, Davis JL et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23(10), 1043-1053 (2012).
34. Ohno M, Natsume A, Ichiro Iwami K et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 101(12), 2518-2524 (2010).
35. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front. Oncol. 4, 385 (2014).
36. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33(17), 1974 -1982 (2015).
37. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24(2), 106-113 (2001).
38. Amano T, Kajiwara K, Yoshikawa K et al. Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model. J. Neurosurg. 106, 638-645 (2007).
39. Aoki H, Mizuno M, Natsume A et al. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol. Immunother. 50, 463-468 (2001).
40. Cho HI, Kim EK, Park SY, Lee SK, Hong YK, Kim TG. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett. 258, 189-198 (2007).
41. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol. Immunother. 55, 1491-1503 (2006).
42. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol. Immunother. 57, 1827-1835 (2008).
43. Clavreul A, Delhaye M, Jadaud E, Menei P. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model. J. Neurooncol. 79, 9-17 (2006).
44. Driessens G, Hamdane M, Cool V, Velu T, Bruyns C. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colonystimulating factor. Cancer Res. 64, 8435-8442 (2004).
45. Fujita M, Zhu X, Ueda R et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res. 69, 1587-1595 (2009).
46. Grauer OM, Sutmuller RPM, Van Maren W et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int. J. Cancer 122, 1794-1802 (2008).
47. Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M. MIP-1α antagonizes the effect of a GM-CSFenhanced subcutaneous vaccine in a mouse glioma model. J. Neurooncol. 66, 147-154 (2004).
48. Insug O, Ku G, Ertl HCJ, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res. 22(2A), 613-621 (2002).
49. Jouanneau E, Poujol D, Gulia S et al. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol. 55, 254-267 (2006).
50. Kim CH, Hong MJ, Park SD et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol. Immunother. 55(11), 1309-1319 (2006).
51. Kim CH, Yoon JS, Sohn HJ et al. Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNAelectroporated dendritic cells in a murine glioma model. Cancer Lett. 250, 276-283 (2007).
52. Kim C-H, Woo S-J, Park J-S et al. Enhanced antitumour immunity by combined use of temozolomide and TATsurvivin pulsed dendritic cells in a murine glioma. Immunology 122, 615-622 (2007).
53. Kjaergaard J, Wang L-X, Kuriyama H, Shu S, Plautz GE. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J. Neurosurg. 103, 156-164 (2005).
54. Kuwashima N, Nishimura F, Eguchi J et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J. Immunol. 175, 2730-2740 (2005).
55. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90, 1115-1124 (1999).
56. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J. Neurooncol. 51, 1-9 (2001).
57. Pellegatta S, Finocchiaro G. Cell therapies in neurooncology. Neurol. Sci. 26, 43-45 (2005).
58. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63, 8487-8491 (2003).
59. Saito R, Mizuno M, Nakahara N et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int. J. Cancer 111, 777-782 (2004).
60. Takagi Y, Kikuchi T, Niimura M, Ohno T. Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res. 23, 2553-2558 (2003).
61. Witham TF, Erff ML, Okada H et al. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50, 1327-1335 (2002).
62. Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cellassociated antigens. Stem Cells 27, 1734-1740 (2009).
63. Yamanaka R, Zullo S, Ramsey J et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 97, 611-618 (2002).
64. Zhang Z, Tang L-L, Zhan R-Y, Tong Y, Yao H-P, Du L-A. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA. J. Zhejiang Univ. Sci. 5, 1298-1303 (2004).
65. Zhu X, Lu C, Xiao B, Qiao J, Sun Y. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats. J. Neurooncol. 74, 9-17 (2005).
66. Maes W, Rosas GG, Verbinnen B et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol. 11, 529-542 (2009).
67. Jiang X-B, Lu X-L, Hu P, Liu R-E. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 27, 6210-6216 (2009).
68. Saka M, Amano T, Kajiwara K et al. Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice. J. Neurosurg. 113, 270-279 (2010).
69. Kim T-G, Kim C-H, Park J-S et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin. Vaccine Immunol. 17, 143-153 (2010).
70. Xiao Z-Y, Tang H, Xu Z-M et al. An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors. Cancer Biol. Ther. 11, 974-980 (2011).
71. Mineharu Y, King GD, Muhammad AKMG et al. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin. Cancer Res. 17, 4705-4718 (2011).
72. Feng E, Gao H, Su W, Yu C. Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells. Neural Regen. Res. 7, 1498-1506 (2012).
73. Zhang H, Tian M, Xiu C, Wang Y, Tang G. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model. Oncol. Res. 20, 447-455 (2013).
74. Peng W, Nan Z, Liu Y et al. Dendritic cells transduced with CPEB4 induced antitumor immune response. Exp. Mol. Pathol. 97, 273-278 (2014).
75. Bu N, Wu H, Zhang G et al. Exosomes from dendritic cells loaded with chaperone-rich cell lysates elicit a potent T cell immune response against intracranial glioma in mice. J. Mol. Neurosci. 56(3), 631-643 (2015).
76. Li M, Wang B, Wu Z et al. A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma. Tumor Biol. 36(7), 5497-5503 (2015).
77. Bloch O, Crane CA, Fuks Y et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a Phase II, single-arm trial. Neuro Oncol. 16(2), 274-279 (2014).
78. Buchroithner J, Pichler J, Marosi C et al. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. Int. J. Clin. Pharmacol. Ther. 52(1), 76-77 (2014).
79. Ishikawa E, Muragaki Y, Yamamoto T et al. Phase I/ IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J. Neurosurg. 121(3), 543-553 (2014).
80. Mitchell DA, Batich KA, Gunn MD et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519, 366-369 (2015).
81. Phuphanich S, Wheeler CJ, Rudnick JD et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol. Immunother. 62(1), 125-135 (2013).
82. Prins RM, Soto H, Konkankit V et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17(6), 1603-1615 (2011).
83. Riedmann EM. Agenus cancer vaccine extends survival of GBM patients. Hum. Vaccin. Immunother. 10(2), 252-253 (2014).
84. Schuster J, Lai RK, Recht LD et al. A Phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17(6), 854-861 (2015).
85. Vik-Mo EO, Nyakas M, Mikkelsen BV et al. Therapeutic vaccination against autologous cancer stem cells with mRNAtransfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 62(9), 1499-1509 (2013).
86. Colombo F, Barzon L, Franchin E et al. Combined HSVTK/ IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 12(10), 835-848 (2005).
87. Kroeger KM, Muhammad AK, Baker GJ et al. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov. Med. 10(53), 293-304 (2010).
88. Kwiatkowska A, Nandhu MS, Behera P, Chiocca EA, Viapiano MS. Strategies in gene therapy for glioblastoma. Cancers (Basel) 5(4), 1271-1305 (2013).
89. Okada H, Pollack IF, Lotze MT et al. Gene therapy of malignant gliomas: a Phase I study of IL-4-HSV-TK genemodified autologous tumor to elicit an immune response. Hum. Gene Ther. 11(4), 637-653 (2000).
90. Palu G, Cavaggioni A, Calvi P et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. 6(3), 330-337 (1999).
91. Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7(10), 859-866 (2000).
92. Sonabend AM, Ulasov IV, Lesniak MS. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther. Mol. Biol. 11(A), 79-92 (2007).
93. Tobias A, Ahmed A, Moon KS, Lesniak MS. The art of gene therapy for glioma: a review of the challenging road to the bedside. J. Neurol. Neurosurg. Psychiatry 84(2), 213-222 (2013).
94. Prins RM, Wang X, Soto H et al. Comparison of gliomaassociated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J. Immunother. 36(2), 152-157 (2013).
95. Akiyama Y, Oshita C, Kume A et al. Alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a Phase I clinical trial. BMC Cancer 12, 623 (2012).
96. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005).
97. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004).
98. Crane CA, Han SJ, Ahn B et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin. Cancer Res. 19(1), 205-214 (2013).
99. Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J. Neurosurg. 108(5), 963-971 (2008).
100. Morita S, Oka Y, Tsuboi A et al. A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J. Clin. Oncol. 36(4), 231-236 (2006).
101. Okada H, Butterfield LH, Hamilton RL et al. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin. Cancer Res. 21(2), 286-294 (2015).
102. Pollack IF, Jakacki RI, Butterfield LH et al. Antigenspecific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J. Clin. Oncol. 32(19), 2050-2058 (2014).
103. Schuessler A, Smith C, Beagley L et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74(13), 3466-3476 (2014).
104. Brown CE, Badie B, Barish ME et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21(18), 4062-4072 (2015).
105. Massimino M, Biassoni V, Miceli R et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J. Neurooncol. 118(2), 305-312 (2014).
106. Sampson JH, Schmittling RJ, Archer GE et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS ONE 7(2), e31046 (2012).
107. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
108. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
109. Bloch O. Immunotherapy for malignant gliomas. Cancer Treat. Res. 163, 143-158 (2015).
110. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
111. Fecci PE, Ochiai H, Mitchell DA et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13(7), 2158-2167 (2007).
112. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA- 4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
113. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
114. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173(2), 945-954 (2004).
115. Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616-622 (2013).
116. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012).
117. Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti- CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
118. Vom Berg J, Vrohlings M, Haller S et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J. Exp. Med. 210(13), 2803-2811 (2013).
119. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 35(5), 385-389 (2012).
120. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
121. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
122. Zeng J, See AP, Phallen J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86(2), 343-349 (2013).
123. Wainwright DA, Chang AL, Dey M et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20(20), 5290-5301 (2014).
124. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 6(3), 914-933 (2014).
125. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
126. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castrationresistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813-1821 (2013).
127. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti- CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37(5), 485-498 (2010).
128. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
129. Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas - a clinical review of three selected approaches. Pharmacol. Ther. 139(3), 341-358 (2013).
130. Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2), 474-485 (2010).
131. Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE 5(3), e9750 (2010).
132. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64(24), 9160-9166 (2004).
133. Curtin JF, Liu N, Candolfi M et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6(1), e10 (2009).
134. Candolfi M, Yagiz K, Wibowo M et al. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin. Cancer Res. 20(6), 1555-1565 (2014).
135. Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol. Ther. 22(2), 251-256 (2014).
136. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12(12), 860-875 (2012).
137. Okura H, Smith C, Rutka J. Gene therapy for malignant glioma. Mol. Cell Ther. 2(1), 1-19 (2014).
138. Oldfield EH, Ram Z, Culver KW, Blaese RM, Devroom HL, Anderson WF. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4(1), 39-69 (1993).
139. Puntel M, Muhammad AK, Candolfi M et al. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J. Virol. 84(12), 6007-6017 (2010).
140. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev. Neurother. 9(4), 505-517 (2009).
141. Markert JM, Liechty PG, Wang W et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM. Mol. Ther. J. Am. Soc. Gene Ther. 17(1), 199-207 (2009).
142. Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7(10), 867-874 (2000).
143. Kirn D, Hermiston T, Mccormick F. ONYX-015: clinical data are encouraging. Nat. Med. 4(12), 1341-1342 (1998).
144. Chiocca EA, Abbed KM, Tatter S et al. A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. J. Am. Soc. Gene Ther. 10(5), 958-966 (2004).
145. Fueyo J, Gomez-Manzano C, Alemany R et al. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene 19(1), 2-12 (2000).
146. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64(14), 4919-4926 (2004).
147. Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 18(1), 69-81 (2012).
148. Allen C, Paraskevakou G, Iankov I et al. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol. Ther. J. Am. Soc. Gene Ther. 16(9), 1556-1564 (2008).
149. Uchida H, Marzulli M, Nakano K et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther. 21(3), 561-569 (2013).
150. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol. Ther. 4(4), 356-364 (2001).
151. Qin XQ, Tao N, Dergay A et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl Acad. Sci. USA 95(24), 14411-14416 (1998).
152. Mizuno M, Yoshida J. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells. Cancer Immunol. Immunother. 47(4), 227-232 (1998).
153. Yoshida J, Mizuno M, Fujii M et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum. Gene Ther. 15(1), 77-86 (2004).
154. Chiocca EA, Smith KM, McKinney B et al. A Phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol. Ther. 16(3), 618-626 (2008).
155. Ehtesham M, Samoto K, Kabos P et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther. 9(11), 925-934 (2002).
156. Chen B, Timiryasova TM, Andres ML et al. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther. 7(11), 1437-1447 (2000).
157. Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184(5), 1953-1962 (1996).
158. Ali S, Curtin JF, Zirger JM et al. Inflammatory and antiglioma effects of an adenovirus expressing human soluble Fmslike tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol. Ther. 10(6), 1071-1084 (2004).
159. Ali S, King GD, Curtin JF et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 65(16), 7194-7204 (2005).
160. King GD, Muhammad AK, Larocque D et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol. Ther. 19(10), 1793-1801 (2011).
161. Candolfi M, Curtin JF, Yagiz K et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 13(10), 947-960 (2011).
162. King GD, Muhammad AK, Curtin JF et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 10(1), 19-31 (2008).
163. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J. Immunol. 156(10), 3721-3726 (1996).
164. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249, 918-921 (1990).
165. Gustafsson K, Junevik K, Werlenius O, Holmgren S, Karlsson- Parra A, Andersson P-O. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cellattracting chemokine profile. Scand. J. Immunol. 74, 318-326 (2011).
166. Shimizu K, Fujii S-I. DC therapy induces long-term NK reactivity to tumors via host DC. Eur. J. Immunol. 39, 457-468 (2009).
167. Lafferty KJ, Warren HS, Woolnough JA. A mediator acting as a costimulator for the development of cytotoxic responses in vitro. Adv. Exp. Med. Biol. 114, 497-501 (1979).
168. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J. Biomed. Biotech. 2012, 1-17 (2012).
169. Joffre O, Nolte MA, Spörri R, Reis E Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227, 234-247 (2009).
170. Cohen PA, Koski GK, Czerniecki BJ et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood 112, 1832-1843 (2008).
171. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. Alphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937 (2004).
172. Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann. NY Acad. Sci. 1174, 18-23 (2009).
173. Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol. Med. Chir. (Tokyo) 53, 741-754 (2013).
174. Ohlfest JR, Andersen BM, Litterman AJ et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J. Immunol. 190(2), 613-620 (2013).
175. Yamanaka R, Zullo SA, Tanaka R, Ramsey J, Blaese M, Xanthopoulos KG. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg. Focus 9, e7 (2000).
176. Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165, 302-319 (1987).
177. Zeppernick F, Ahmadi R, Campos B et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14(1), 123-129 (2008).
178. Pallini R, Ricci-Vitiani L, Montano N et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117(1), 162-174 (2011).
179. Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011).
180. Esparza R, Azad TD, Feroze AH, Mitra SS, Cheshier SH. Glioblastoma stem cells and stem cell-targeting immunotherapies. J. Neurooncol. 123(3), 449-457 (2015).
181. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16(6), 748-754 (2009).
182. Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J. Transl. Med. 3, 38 (2005).
183. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 9(11), 4247-4254 (2003).
184. Mishima K, Johns TG, Luwor RB et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61(14), 5349-5354 (2001).
185. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid. 7, 93-103 (2012).
186. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
187. Reardon DA, Wucherpfennig KW, Freeman G et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev. Vaccines 12(6), 597-615 (2013).
188. Caudill MM, Li Z. HSPPC-96: a personalised cancer vaccine. Expert Opin. Biol. Ther. 1(3), 539-547 (2001).
189. Binder RJ, Srivastava PK. Essential role of CD91 in representation of gp96-chaperoned peptides. Proc. Natl Acad. Sci. USA 101(16), 6128-6133 (2004).
190. Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol. 9(7), 977-990 (2013).
191. Jouanneau E, Black KL, Veiga L et al. Intrinsically de-sialylated CD103(+) CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunol. Immunother. 63(9), 911-924 (2014).
192. Ikeda H, Shiku H. Antigen-receptor gene-modified T cells for treatment of glioma. Adv. Exp. Med. Biol. 746, 202-215 (2012).
193. Chekmasova AA, Rao TD, Nikhamin Y et al. Successful eradication of established peritoneal ovarian tumors in SCIDBeige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16(14), 3594-3606 (2010).
194. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116(19), 3875-3886 (2010).
195. Zhao Y, Wang QJ, Yang S et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183(9), 5563-5574 (2009).
196. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4(5), 388-399 (2002).
197. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER- 2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64(14), 4980-4986 (2004).
198. Ammi R, de Waele J, Willemen Y et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol. Ther. 146, 120-131 (2015).
199. Black PL, Hartmann D, Pennington R et al. Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC]. Int. J. Immunopharmacol. 14(8), 1341-1353 (1992).
200. Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv. Exp. Med. Biol. 746, 95-108 (2012).
201. AA Gaspari, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 8(5), 467-474 (2009).
202. Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J. Immunother. 34(3), 264-269 (2011).
203. Rosenfeld MR, Chamberlain MC, Grossman SA et al. A multi-institution Phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 12(10), 1071-1077 (2010).
204. Carpentier A, Metellus P, Ursu R et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a Phase II study. Neuro Oncol. 12(4), 401-408 (2010).
205. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
206. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J. Neurooncol. 123(3), 339-346 (2015).
207. Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN. Biomarkers for glioma immunotherapy: the next generation. J. Neurooncol. 123(3), 359-372 (2015).